Related Experiment Video
Updated: Aug 10, 2025
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer
Xin Zhang1, Zheng Xu1, Xiangpeng Dai2,3
1Department of Pathology, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China.
Abstract:
The mutation of the crucial genes such as tumor suppressors or oncogenes plays an important role in the initiation and development of tumors. The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to activate the immune system by activating CD4+ and CD8+ T cells. Neoantigen-based peptide vaccines have exhibited exciting therapeutic effects in treating various cancers alone or in combination with other therapeutic strategies. Furthermore, antigen-loaded DC vaccines are more powerful in inducing stronger immune responses than vaccines generated by antigens and adjuvants. Therefore, neoantigen-based dendritic cell (DC) vaccines could achieve promising effects in combating some malignant tumors. In this review, we summarized and discussed the recent research progresses of the neoantigen, neoantigen-based vaccines, and DC-based vaccine in pancreatic cancers (PCs). The combination of the neoantigen and DC-based vaccine in PC was also highlighted. Therefore, our work will provide more detailed evidence and novel opinions to promote the development of a personalized neoantigen-based DC vaccine for PC.
Insights
Neoantigen-based dendritic cell (DC) vaccines show promise for treating pancreatic cancer. This review highlights research on neoantigens and DC vaccines, supporting personalized treatment development.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Tumorigenesis involves mutations in critical genes like tumor suppressors and oncogenes.
- Non-synonymous mutations yield neoantigens, activating CD4+ and CD8+ T cells for anti-tumor immunity.
Purpose of the Study:
- To review recent advancements in neoantigens, neoantigen-based vaccines, and dendritic cell (DC) vaccines for pancreatic cancers (PCs).
- To explore the potential of combining neoantigen and DC-based vaccines for personalized PC therapy.
Main Methods:
- Literature review summarizing research on neoantigens, peptide vaccines, and DC vaccines in pancreatic cancer.
- Analysis of immune activation mechanisms involving neoantigens and T cells (CD4+, CD8+).
Main Results:
- Neoantigen-based peptide vaccines demonstrate therapeutic potential in various cancers.
- Antigen-loaded DC vaccines elicit stronger immune responses compared to antigen/adjuvant vaccines.
- Neoantigen-based DC vaccines show promise for treating malignant tumors, including pancreatic cancer.
Conclusions:
- Neoantigen-based DC vaccines offer a promising strategy for combating pancreatic cancer.
- Combining neoantigens with DC vaccines could enhance therapeutic efficacy in PCs.
- This review provides evidence to advance personalized neoantigen-based DC vaccine development for PC.
